Cegedim's 83% Earnings Leap Is a Base Effect — the Real Story Is a Pre-Bought Server Room
A €155M French health-IT minnow leans on cost control, an e-invoicing tailwind and a data-center buildout that management funded early because hardware prices are soaring.
ALCGM.PA · Earnings Call · 2026-09-24
A headlight number that management promptly dims
The headline out of Cegedim's H1 2026 release reads like a breakout: operating income up 83%, net income group share up more than fourfold to €5.4M from €1.2M. Management, to its credit, refuses to sell it that way. The same CEO who walks through the P&L tells you the mechanical cause — last year's first half carried a €9M non-recurring gain, €7.4M of it from a redundancy scheme in the French pharmacy software arm, while this year's comparable bucket is only €2.4M. "This leads to this very important increase in the operating income, which stands at EUR 17.3 million in H1 2026, compared with EUR 9.5 million last year. It is a change of EUR 7.8 million or almost 83% improvement," he says, before attributing it to cost control and the reduced non-recurring drag. Strip the noise and the durable number is the adjusted operating margin: 6.1% versus 5.7%, on revenue of €324.8M that grew just 0.7% reported and 0.8% like-for-like. This is a margin-repair story dressed as a growth story, and the honest framing is the most interesting thing in it.
The cash signal that matters: buying servers before they get more expensive
What the operating line buries, the cash-flow statement confesses. Operating cash flow ticked up modestly to €58.9M, but capital outlays jumped from €36.2M to €52M. Two items drive that, and one is a quiet macro bet. Cegedim is building a new data centers facility near Paris, and management pre-purchased servers ahead of schedule. The reason is oddly topical for a French health-IT company: "We booked in advance some of them, because prices are soaring, so we wanted to be sure to have the best prices we could and buy a bit in advance." That sentence is a small-cap echoing the hardware-cost inflation the wider market spent the last several quarters fretting over. It also explains why net debt fell anyway — down 17% to roughly €150M — thanks to the very strong cash generation booked back in H2 2025, not this period. Headline leverage improved even as the company wrote bigger checks.
The tailwind nobody in French healthcare software can ignore
The operating engine underneath is business services, up about 4% and, crucially, firing on all three cylinders: HR software, e-business and BPO. The accelerant is France's e-invoicing mandate, which went live on 1 September — just weeks before this call. Management notes Q2 revenue swung to a €4M gain after a weak Q1, "partly due to the reform of the e-invoicing in France that started in September 1st." Companies caught in the first wave are arriving as project clients. That is a genuine multi-quarter runway, not a one-off.
The other green shoots are new enough to be visible in the keyword set for the first time: the C MEDIA España marketing launch in Spain, the Médoucine appointment-booking platform consolidated from 1 May, and a Spain/doctor-software business the CEO says "is working very well." These are being paid for now — the marketing unit's adjusted EBIT fell to €6.1M from €9.2M as Spain launch costs and a new European data warehouse weighed — which is exactly the kind of invest-ahead decision that separates a real strategy from harvest mode.
AI as a cost lever, not a slogan
Cegedim's AI talk is unusually operational. Rather than an AI-revenue narrative, the CEO frames it three ways, and the most consequential is internal: "It is due to various things, among which the AI development in the company," he says of a 113-person headcount reduction, with offshore now roughly 28% of the workforce. The productivity story is real enough to show up in the payroll line, which fell €1.5M. On the product side, the group is integrating AI into existing software — an AI assistant and phone agent inside the Maiia suite, and Claude Bernard's new IA offering — alongside fraud detection in third-party payer, which continues to drive that business. This is AI as margin defense at a company too small to win an arms race on model building.
What management quietly stopped cheering about
The missing fanfare is instructive. The French pharmacy software unit — the one that took the redundancy charge a year ago — is still the drag: the Pharmacy segment improved from a €8.7M loss to a €6.8M loss, with sales muted because the restructuring sapped commercial traction. And Cegedim Santé remains deep in the red at −€5.1M, bleeding on legacy-solution churn while management invests in the future. H2 is meant to bring roughly €4M of Ségur subsidies to soften that. The outsourcing contract termination and a demanding trading comparison in Cloud & Support also left that unit at a small loss. A year ago these units were framed with more optimism; today the tone is patience.
That is the tension in the whole report: management is candid that the bottom line is flattered, the guiding growth target is a modest "above 2%" like-for-like, yet the underlying levers — an e-invoicing mandate, an offshore-and-AI cost base, a pre-bought server fleet, and fresh Iberian expansion — are all pointing the right way. For a company with a €155M market cap and no news coverage in the window, this is a slow-burn execution story rather than a catalyst event. The Q3 revenue print on 22 October is the next real checkpoint; the interesting question is whether the e-invoicing project flow converts into the recurring revenue the margin story now depends on.